Physician profile
Albert C Tanlim
NPI 1659342665
$4,608.95
in general payments reported to CMS, 2019-2025
22 companies · $755 in 2025
The $755 reported for 2025 was more than what 87% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $776 · 2021: $751 · 2023: $501 · 2024: $957 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169 · Education: $43.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.57 |
| Education | $43.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $986.62 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Novo Nordisk INC | $945.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $563.02 | 2020-2025 | Airsupra, Breztri, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.23 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $426.49 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $216.02 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $163.00 | 2021-2025 | Vraylar |
| Amgen INC. | $157.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $134.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $94.39 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.98 | 2021-2024 | Xifaxan |
| Dexcom, INC. | $65.45 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $43.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.61 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.11 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.92 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.29 | 2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $28.49 | 2019-2020 | |
| Dynavax Technologies Corporation | $20.62 | 2024 | Heplisav-B |
| Mylan Specialty L.P. | $18.80 | 2024 | Yupelri |
| Avanir Pharmaceuticals, INC. | $16.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Tanlim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.